Brad Spellberg
Corporate Officer/Principal chez University of California, Los Angeles
Postes actifs de Brad Spellberg
Sociétés | Poste | Début | Fin |
---|---|---|---|
University of California, Los Angeles | Corporate Officer/Principal | - | - |
Historique de carrière de Brad Spellberg
Anciens postes connus de Brad Spellberg
Sociétés | Poste | Début | Fin |
---|---|---|---|
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | Directeur Technique/Scientifique/R&D | - | - |
Statistiques
Internationale
Etats-Unis | 3 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 1 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | Health Technology |
- Bourse
- Insiders
- Brad Spellberg
- Expérience